JP2010523727A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010523727A5 JP2010523727A5 JP2010503397A JP2010503397A JP2010523727A5 JP 2010523727 A5 JP2010523727 A5 JP 2010523727A5 JP 2010503397 A JP2010503397 A JP 2010503397A JP 2010503397 A JP2010503397 A JP 2010503397A JP 2010523727 A5 JP2010523727 A5 JP 2010523727A5
- Authority
- JP
- Japan
- Prior art keywords
- propanamide
- methyl
- tert
- pyridin
- methylpiperidin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 150000001875 compounds Chemical class 0.000 claims description 7
- LKJPYSCBVHEWIU-UHFFFAOYSA-N N-[4-cyano-3-(trifluoromethyl)phenyl]-3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methylpropanamide Chemical compound C=1C=C(C#N)C(C(F)(F)F)=CC=1NC(=O)C(O)(C)CS(=O)(=O)C1=CC=C(F)C=C1 LKJPYSCBVHEWIU-UHFFFAOYSA-N 0.000 claims 52
- -1 Benzo [d] oxazol-5-yl Chemical group 0.000 claims 44
- 125000003352 4-tert-butyl benzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])*)C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 claims 13
- 125000005605 benzo group Chemical group 0.000 claims 3
- NCJXQSNROJRSSL-UHFFFAOYSA-N tert-butyl n-(1,3-thiazol-2-yl)carbamate Chemical compound CC(C)(C)OC(=O)NC1=NC=CS1 NCJXQSNROJRSSL-UHFFFAOYSA-N 0.000 claims 3
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims 2
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 claims 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N dimethylmethane Natural products CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 claims 2
- 239000001294 propane Substances 0.000 claims 2
- ONCMXDQXYISJBI-UHFFFAOYSA-N 2-(1h-indazol-4-yl)-n-[[2-(4-methylpiperidin-1-yl)-6-(trifluoromethyl)pyridin-3-yl]methyl]propanamide Chemical compound C=1C=CC=2NN=CC=2C=1C(C)C(=O)NCC1=CC=C(C(F)(F)F)N=C1N1CCC(C)CC1 ONCMXDQXYISJBI-UHFFFAOYSA-N 0.000 claims 1
- KWJNGOYALHIESJ-UHFFFAOYSA-N 2-(1h-indazol-5-yl)-n-[[2-(4-methylpiperidin-1-yl)-6-(trifluoromethyl)pyridin-3-yl]methyl]propanamide Chemical compound C=1C=C2NN=CC2=CC=1C(C)C(=O)NCC1=CC=C(C(F)(F)F)N=C1N1CCC(C)CC1 KWJNGOYALHIESJ-UHFFFAOYSA-N 0.000 claims 1
- UWTKKDFQVFERKC-UHFFFAOYSA-N 2-(1h-indazol-6-yl)-n-[[2-(4-methylpiperidin-1-yl)-6-(trifluoromethyl)pyridin-3-yl]methyl]propanamide Chemical compound C=1C=C2C=NNC2=CC=1C(C)C(=O)NCC1=CC=C(C(F)(F)F)N=C1N1CCC(C)CC1 UWTKKDFQVFERKC-UHFFFAOYSA-N 0.000 claims 1
- WVTZUKHRJVQGIT-UHFFFAOYSA-N 2-(1h-indazol-7-yl)-n-[[2-(4-methylpiperidin-1-yl)-6-(trifluoromethyl)pyridin-3-yl]methyl]propanamide Chemical compound C=1C=CC=2C=NNC=2C=1C(C)C(=O)NCC1=CC=C(C(F)(F)F)N=C1N1CCC(C)CC1 WVTZUKHRJVQGIT-UHFFFAOYSA-N 0.000 claims 1
- TUPYZUVCWJUOSV-UHFFFAOYSA-N n-[(2-butoxy-6-tert-butylpyridin-3-yl)methyl]-2-(1h-indazol-5-yl)propanamide Chemical compound CCCCOC1=NC(C(C)(C)C)=CC=C1CNC(=O)C(C)C1=CC=C(NN=C2)C2=C1 TUPYZUVCWJUOSV-UHFFFAOYSA-N 0.000 claims 1
- QLNJFJADRCOGBJ-UHFFFAOYSA-N propionamide Chemical compound CCC(N)=O QLNJFJADRCOGBJ-UHFFFAOYSA-N 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 239000012453 solvate Substances 0.000 claims 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- 208000011117 substance-related disease Diseases 0.000 description 22
- 208000002193 Pain Diseases 0.000 description 20
- 206010013663 drug dependence Diseases 0.000 description 15
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 13
- 201000010099 disease Diseases 0.000 description 12
- 208000007848 Alcoholism Diseases 0.000 description 11
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 10
- 239000003814 drug Substances 0.000 description 10
- 206010020853 Hypertonic bladder Diseases 0.000 description 8
- 208000009722 Overactive Urinary Bladder Diseases 0.000 description 8
- 102100029613 Transient receptor potential cation channel subfamily V member 1 Human genes 0.000 description 8
- 108050004388 Transient receptor potential cation channel subfamily V member 1 Proteins 0.000 description 8
- 230000004770 neurodegeneration Effects 0.000 description 8
- 208000015122 neurodegenerative disease Diseases 0.000 description 8
- 208000020629 overactive bladder Diseases 0.000 description 8
- 230000036407 pain Effects 0.000 description 8
- 238000011282 treatment Methods 0.000 description 8
- 206010013654 Drug abuse Diseases 0.000 description 7
- 201000007930 alcohol dependence Diseases 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 6
- 208000000094 Chronic Pain Diseases 0.000 description 5
- 206010061218 Inflammation Diseases 0.000 description 5
- 206010046543 Urinary incontinence Diseases 0.000 description 5
- 208000005298 acute pain Diseases 0.000 description 5
- 230000004054 inflammatory process Effects 0.000 description 5
- 208000004296 neuralgia Diseases 0.000 description 5
- 208000021722 neuropathic pain Diseases 0.000 description 5
- 208000024827 Alzheimer disease Diseases 0.000 description 4
- 208000030814 Eating disease Diseases 0.000 description 4
- 208000019454 Feeding and Eating disease Diseases 0.000 description 4
- 208000004454 Hyperalgesia Diseases 0.000 description 4
- 208000019695 Migraine disease Diseases 0.000 description 4
- 208000018737 Parkinson disease Diseases 0.000 description 4
- 108010025083 TRPV1 receptor Proteins 0.000 description 4
- 239000000556 agonist Substances 0.000 description 4
- YKPUWZUDDOIDPM-SOFGYWHQSA-N capsaicin Chemical compound COC1=CC(CNC(=O)CCCC\C=C\C(C)C)=CC=C1O YKPUWZUDDOIDPM-SOFGYWHQSA-N 0.000 description 4
- 230000007278 cognition impairment Effects 0.000 description 4
- 208000010877 cognitive disease Diseases 0.000 description 4
- 235000014632 disordered eating Nutrition 0.000 description 4
- 210000001508 eye Anatomy 0.000 description 4
- 210000000936 intestine Anatomy 0.000 description 4
- 206010027175 memory impairment Diseases 0.000 description 4
- 206010027599 migraine Diseases 0.000 description 4
- 229940005483 opioid analgesics Drugs 0.000 description 4
- 208000017520 skin disease Diseases 0.000 description 4
- 208000009935 visceral pain Diseases 0.000 description 4
- 208000006820 Arthralgia Diseases 0.000 description 3
- 102000003566 TRPV1 Human genes 0.000 description 3
- 101150016206 Trpv1 gene Proteins 0.000 description 3
- 206010001584 alcohol abuse Diseases 0.000 description 3
- 208000025746 alcohol use disease Diseases 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 201000006417 multiple sclerosis Diseases 0.000 description 3
- 210000002850 nasal mucosa Anatomy 0.000 description 3
- 201000001119 neuropathy Diseases 0.000 description 3
- 230000007823 neuropathy Effects 0.000 description 3
- 208000033808 peripheral neuropathy Diseases 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 206010063409 Acarodermatitis Diseases 0.000 description 2
- 206010006482 Bronchospasm Diseases 0.000 description 2
- 208000032841 Bulimia Diseases 0.000 description 2
- 206010006550 Bulimia nervosa Diseases 0.000 description 2
- 206010006895 Cachexia Diseases 0.000 description 2
- 206010011224 Cough Diseases 0.000 description 2
- 201000004624 Dermatitis Diseases 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- IKYCZSUNGFRBJS-UHFFFAOYSA-N Euphorbia factor RL9 = U(1) = Resiniferatoxin Natural products COC1=CC(O)=CC(CC(=O)OCC=2CC3(O)C(=O)C(C)=CC3C34C(C)CC5(OC(O4)(CC=4C=CC=CC=4)OC5C3C=2)C(C)=C)=C1 IKYCZSUNGFRBJS-UHFFFAOYSA-N 0.000 description 2
- 206010015946 Eye irritation Diseases 0.000 description 2
- 208000009889 Herpes Simplex Diseases 0.000 description 2
- 208000035154 Hyperesthesia Diseases 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 206010020843 Hyperthermia Diseases 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 208000001132 Osteoporosis Diseases 0.000 description 2
- 206010035664 Pneumonia Diseases 0.000 description 2
- 208000004880 Polyuria Diseases 0.000 description 2
- 208000003251 Pruritus Diseases 0.000 description 2
- 208000025747 Rheumatic disease Diseases 0.000 description 2
- 241000447727 Scabies Species 0.000 description 2
- 206010040880 Skin irritation Diseases 0.000 description 2
- 208000007107 Stomach Ulcer Diseases 0.000 description 2
- 206010047642 Vitiligo Diseases 0.000 description 2
- 230000000172 allergic effect Effects 0.000 description 2
- 206010053552 allodynia Diseases 0.000 description 2
- 208000022531 anorexia Diseases 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 208000010668 atopic eczema Diseases 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 206010006451 bronchitis Diseases 0.000 description 2
- 230000007885 bronchoconstriction Effects 0.000 description 2
- 229960002504 capsaicin Drugs 0.000 description 2
- 235000017663 capsaicin Nutrition 0.000 description 2
- 210000000748 cardiovascular system Anatomy 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 206010061428 decreased appetite Diseases 0.000 description 2
- 230000035619 diuresis Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 206010015037 epilepsy Diseases 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 231100000013 eye irritation Toxicity 0.000 description 2
- 201000005917 gastric ulcer Diseases 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 230000036031 hyperthermia Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 230000037023 motor activity Effects 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 230000000926 neurological effect Effects 0.000 description 2
- 201000008482 osteoarthritis Diseases 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- DSDNAKHZNJAGHN-UHFFFAOYSA-N resinferatoxin Natural products C1=C(O)C(OC)=CC(CC(=O)OCC=2CC3(O)C(=O)C(C)=CC3C34C(C)CC5(OC(O4)(CC=4C=CC=CC=4)OC5C3C=2)C(C)=C)=C1 DSDNAKHZNJAGHN-UHFFFAOYSA-N 0.000 description 2
- DSDNAKHZNJAGHN-MXTYGGKSSA-N resiniferatoxin Chemical compound C1=C(O)C(OC)=CC(CC(=O)OCC=2C[C@]3(O)C(=O)C(C)=C[C@H]3[C@@]34[C@H](C)C[C@@]5(O[C@@](O4)(CC=4C=CC=CC=4)O[C@@H]5[C@@H]3C=2)C(C)=C)=C1 DSDNAKHZNJAGHN-MXTYGGKSSA-N 0.000 description 2
- 229940073454 resiniferatoxin Drugs 0.000 description 2
- 208000023504 respiratory system disease Diseases 0.000 description 2
- 208000005687 scabies Diseases 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 230000036556 skin irritation Effects 0.000 description 2
- 231100000475 skin irritation Toxicity 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 201000009032 substance abuse Diseases 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 230000008733 trauma Effects 0.000 description 2
- 210000003932 urinary bladder Anatomy 0.000 description 2
- RLWGDRLXZSLGHV-UHFFFAOYSA-N 1-[[4-(2-aminoethoxy)-3-methoxyphenyl]methyl]-3-[(4-tert-butylphenyl)methyl]urea Chemical compound C1=C(OCCN)C(OC)=CC(CNC(=O)NCC=2C=CC(=CC=2)C(C)(C)C)=C1 RLWGDRLXZSLGHV-UHFFFAOYSA-N 0.000 description 1
- 208000028698 Cognitive impairment Diseases 0.000 description 1
- 206010012335 Dependence Diseases 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 206010028116 Mucosal inflammation Diseases 0.000 description 1
- 206010062519 Poor quality sleep Diseases 0.000 description 1
- 208000018569 Respiratory Tract disease Diseases 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- 239000002249 anxiolytic agent Substances 0.000 description 1
- 230000000949 anxiolytic effect Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 208000000718 duodenal ulcer Diseases 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 208000002551 irritable bowel syndrome Diseases 0.000 description 1
- 238000002690 local anesthesia Methods 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 210000001331 nose Anatomy 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000009278 visceral effect Effects 0.000 description 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102007018149A DE102007018149A1 (de) | 2007-04-16 | 2007-04-16 | Neue Vanilloid-Rezeptor Liganden und ihre Verwendung zur Herstellung von Arzneimitteln |
| EP2008002997 | 2008-04-15 | ||
| US12/103,667 US8084484B2 (en) | 2007-04-16 | 2008-04-15 | Vanilloid receptor ligands, pharmaceutical compositions containing them, process for making them, and use thereof for treating pain and other conditions |
| PCT/EP2008/003027 WO2008125342A2 (de) | 2007-04-16 | 2008-04-16 | Vanilloid-rezeptor-liganden und ihre verwendung zur herstellung von arzneimitteln |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010523727A JP2010523727A (ja) | 2010-07-15 |
| JP2010523727A5 true JP2010523727A5 (OSRAM) | 2014-11-13 |
Family
ID=41360190
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010503397A Ceased JP2010523727A (ja) | 2007-04-16 | 2008-04-16 | バニロイド受容体リガンドおよび医薬の製造へのその使用 |
Country Status (14)
| Country | Link |
|---|---|
| JP (1) | JP2010523727A (OSRAM) |
| KR (1) | KR20100016593A (OSRAM) |
| CN (1) | CN101679370A (OSRAM) |
| AU (1) | AU2008238250B2 (OSRAM) |
| BR (1) | BRPI0810035A2 (OSRAM) |
| CA (1) | CA2683461A1 (OSRAM) |
| CO (1) | CO6241154A2 (OSRAM) |
| EC (1) | ECSP099692A (OSRAM) |
| IL (1) | IL201505A0 (OSRAM) |
| MX (1) | MX2009011149A (OSRAM) |
| NZ (1) | NZ580411A (OSRAM) |
| RU (1) | RU2498982C2 (OSRAM) |
| WO (1) | WO2008125342A2 (OSRAM) |
| ZA (1) | ZA200907099B (OSRAM) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102007018149A1 (de) | 2007-04-16 | 2008-10-23 | Grünenthal GmbH | Neue Vanilloid-Rezeptor Liganden und ihre Verwendung zur Herstellung von Arzneimitteln |
| AR076752A1 (es) | 2009-05-07 | 2011-07-06 | Gruenenthal Chemie | Fenilureas y fenilamidas sustituidas como ligandos del receptor de vanilloides. |
| US8946204B2 (en) | 2009-05-07 | 2015-02-03 | Gruenenthal Gmbh | Substituted phenylureas and phenylamides as vanilloid receptor ligands |
| AR087302A1 (es) | 2011-07-26 | 2014-03-12 | Gruenenthal Gmbh | Derivados aza heterociclicos sustituidos |
| JP2014521617A (ja) | 2011-07-26 | 2014-08-28 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | バニロイド受容体リガンドとしての置換二環性芳香族カルボキサミドおよび尿素誘導体 |
| EP2776399A1 (en) * | 2011-11-09 | 2014-09-17 | Grünenthal GmbH | Substituted pyrazolyl-based carboxamide and urea derivatives bearing a phenyl moiety substituted with an n-containing group as vanilloid receptor ligands |
| MX355142B (es) * | 2012-03-05 | 2018-04-05 | Dr Reddys Laboratories Ltd | Acetamidas heterociclicas sustituidas como agonistas del receptor opioide kappa (kor). |
| US10351535B2 (en) | 2013-12-20 | 2019-07-16 | Esteve Pharmaceuticals, S.A. | Piperazine derivatives having multimodal activity against pain |
| CN107721919B (zh) * | 2017-10-30 | 2020-12-08 | 中国药科大学 | 苯基喹啉类trpv1拮抗剂及其制备方法和应用 |
| KR102334947B1 (ko) * | 2020-04-22 | 2021-12-06 | 주식회사 제이맥켐 | Trpv1 길항제로서 벤즈이미다졸론계 시남아마이드 유도체 및 이를 유효성분으로 함유하는 통증의 치료 또는 예방용 약학적 조성물 |
| RU2755206C1 (ru) | 2020-05-20 | 2021-09-14 | Федеральное государственное бюджетное учреждение науки Тихоокеанский институт биоорганической химии им. Г.Б. Елякова Дальневосточного отделения Российской академии наук (ТИБОХ ДВО РАН) | Средство пролонгированного анальгетического действия и лекарственный препарат на его основе |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1451156A4 (en) * | 2001-11-27 | 2005-05-25 | Merck & Co Inc | 4-AMINOCHINOLINVERBINDUNGEN |
| CA2476936A1 (en) * | 2002-02-20 | 2003-08-28 | Chih-Hung Lee | Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (vr1) receptor |
| GB0206876D0 (en) * | 2002-03-22 | 2002-05-01 | Merck Sharp & Dohme | Therapeutic agents |
| US6933311B2 (en) * | 2003-02-11 | 2005-08-23 | Abbott Laboratories | Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor |
| US20060211774A1 (en) * | 2003-04-29 | 2006-09-21 | Bennett Simon T | Method of diagnosins a genetic susceptibility for bone damage |
| SE0301446D0 (sv) * | 2003-05-16 | 2003-05-16 | Astrazeneca Ab | New Compounds |
| CA2526387A1 (en) * | 2003-06-12 | 2004-12-23 | Astellas Pharma Inc. | Benzamide derivative or salt thereof |
| US20050113576A1 (en) * | 2003-08-05 | 2005-05-26 | Chih-Hung Lee | Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor |
| GB0322016D0 (en) * | 2003-09-19 | 2003-10-22 | Merck Sharp & Dohme | New compounds |
| US7683076B2 (en) * | 2003-11-08 | 2010-03-23 | Bayer Schering Pharma Aktiengesellschaft | Tetrahydro-quinolinylurea derivatives |
| WO2005073193A1 (en) * | 2004-01-23 | 2005-08-11 | Amgen Inc. | Vanilloid receptor ligands and their use in treatments |
| DE102005023943A1 (de) * | 2005-05-20 | 2006-11-23 | Grünenthal GmbH | Pentafluorsulfanyl-substituierte Verbindung und deren Verwendung zur Herstellung von Arzneimitteln |
| NZ569327A (en) * | 2005-12-28 | 2011-09-30 | Vertex Pharma | 1-(benzo [d] [1,3] dioxol-5-yl) -n- (phenyl) cyclopropane- carboxamide derivatives and related compounds as modulators of ATP-binding cassette transporters for the treatment of cystic fibrosis |
-
2008
- 2008-04-16 KR KR1020097023887A patent/KR20100016593A/ko not_active Ceased
- 2008-04-16 CA CA002683461A patent/CA2683461A1/en not_active Abandoned
- 2008-04-16 JP JP2010503397A patent/JP2010523727A/ja not_active Ceased
- 2008-04-16 MX MX2009011149A patent/MX2009011149A/es active IP Right Grant
- 2008-04-16 RU RU2009142023/04A patent/RU2498982C2/ru not_active IP Right Cessation
- 2008-04-16 AU AU2008238250A patent/AU2008238250B2/en not_active Ceased
- 2008-04-16 BR BRPI0810035A patent/BRPI0810035A2/pt not_active IP Right Cessation
- 2008-04-16 NZ NZ580411A patent/NZ580411A/en not_active IP Right Cessation
- 2008-04-16 WO PCT/EP2008/003027 patent/WO2008125342A2/de not_active Ceased
- 2008-04-16 CN CN200880020483A patent/CN101679370A/zh active Pending
-
2009
- 2009-10-12 ZA ZA2009/07099A patent/ZA200907099B/en unknown
- 2009-10-14 IL IL201505A patent/IL201505A0/en unknown
- 2009-10-16 EC EC2009009692A patent/ECSP099692A/es unknown
- 2009-10-22 CO CO09118505A patent/CO6241154A2/es active IP Right Grant
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010523727A5 (OSRAM) | ||
| US8163936B2 (en) | Treatment of CRTH2-mediated diseases and conditions | |
| ES2244201T3 (es) | Heterociclos de alquilsulfoxido de 4-bencilpiperidina y su uso como antagonistas del receptor de nmda selectivos del subtipo. | |
| RU2498982C2 (ru) | Новые лиганды ванилоидных рецепторов и их применение для изготовления лекарственных средств | |
| CA2645257C (en) | Sulfonyl benzimidazole derivatives | |
| JP4762903B2 (ja) | 新規のベンゾイミダゾール誘導体 | |
| JP2012526061A5 (OSRAM) | ||
| HRP20130128T1 (hr) | Supstituirani aromatski derivati karboksamida i ureje kao ligandi vaniloidnog receptora | |
| US20120196885A1 (en) | New histone deacetylase inhibitors based simultaneously on trisubstituted 1h-pyrroles and aromatic and heteroaromatic spacers | |
| US20080139558A1 (en) | Quinolones useful as inducible nitric oxide synthase inhibitors | |
| US8168668B2 (en) | Compounds | |
| CA2739344A1 (en) | Phenethylamide derivatives and their heterocyclic analogues | |
| JP2008537741A5 (OSRAM) | ||
| US11945796B2 (en) | Substituted pyridine derivatives as SARM1 inhibitors | |
| HRP20110670T1 (hr) | Derivati 4-(2-amino-1-hidroksietil)fenola kao agonisti beta-2 adrenergičkog receptora | |
| JP2010510202A5 (OSRAM) | ||
| CA2669915A1 (en) | Substituted bicyclocarboxyamide compounds | |
| AU2007248341A1 (en) | Benzimidazole modulators of VR1 | |
| ZA200405348B (en) | 4-(piperidyl-and pyrrolidyl-alkyl-ureido)-quinolines as urotensin ii receptor antagonists | |
| JP2010523726A5 (OSRAM) | ||
| CN102015697B (zh) | 酰胺衍生物以及含有该酰胺衍生物的药物组合物 | |
| CA2577818A1 (en) | New heterocyclic amides | |
| WO2009034433A2 (en) | 3-azabicyclo [3.1.0] hexane derivatives as vanilloid receptor ligands | |
| JP2008508250A5 (OSRAM) | ||
| CN101351463A (zh) | 用于治疗trpv1相关病症的2-(苯并咪唑-1-基)-n-(4-苯基噻唑-2-基)乙酰胺衍生物 |